Cellular Intelligence Acquires Novo Nordisk Parkinson's Cell Therapy Program

May 13, 2026
Cellular Intelligence has obtained global rights to Novo Nordisk's clinical-stage Parkinson's cell therapy and will apply its AI platform to accelerate development and manufacturing, while Novo Nordisk takes an equity stake.

Cellular Intelligence has obtained global rights to Novo Nordisk AS's clinical stage allogeneic cell therapy program for Parkinson's disease, announced in a press release. The therapy has received FDA Fast Track Designation and is currently in a Phase 1/2 clinical trial.

Cellular Intelligence plans to apply its AI foundation model to optimize and scale the program's development and manufacturing. The company aims to shorten traditional timelines and reduce costs to accelerate the path to commercialization. Novo Nordisk will become an equity investor in Cellular Intelligence and remains eligible for future milestone payments and royalties.

The cell therapy is derived from pluripotent stem cells and designed to produce dopaminergic progenitor cells for patients with Parkinson's disease. Cellular Intelligence will also appoint Nuno Mendonça, M.D., as Chief Medical Officer to lead clinical advancement of the program.

The company stated that data generated through this program will further train its AI foundation model, which it expects to apply across future cell therapy and regenerative medicine programs.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

05/13
SOPHiA GENETICS and Synnovis Partner to Expand Blood-Based Cancer Testing in the UK
05/13
Elsevier Report Finds Nurses Underrepresented in Clinical AI Adoption
05/13
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at AEPC 2026
05/13
Aon Expands Claims Copilot Platform Globally
05/13
AndzonBio2 and University of Cambridge Partner on Neuroinflammation Therapeutics

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

Superagency in the Workplace: Empowering People to Unlock AI’s Full Potential

This report explores the transformative potential of artificial intelligence in the workplace, emphasizing the readiness of employees versus the slower adaptation of leadership. It highlights the significant productivity growth potential AI offers, akin to historical technological shifts, and discusses the barriers to achieving AI maturity within organizations. The report also examines the role of leadership in steering companies towards effective AI integration and the need for strategic investments to harness AI's full capabilities.

Read more

You May Also Like